- An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes.
- Breen KE, Katona BW, Catchings A, Ranganathan M, Marcell V, Latham A, Yurgelun MB, Stadler ZK.
- Genet Med. 2022 Oct 12:S1098-3600(22)00918-2. doi: 10.1016/j.gim.2022.08.027. Epub ahead of print.
- PMID: 36222830
- PubMed abstract
- Source abstract
- Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status.
- Scott R, González-Martín A.
- OncLive. 2022 Oct 12.
- Review. Interview
- Free Full Text
Conference abstract:
530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.
Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)
Video: Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer. (OncLive TV)